Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions

By sjmartinez • April 8, 2023

Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Adv. 2023 Apr 7:bloodadvances.2023010016. doi: 10.1182/bloodadvances.2023010016. Epub ahead of print. PMID: 37026796.

Tags: Hematology/Oncology, Publications

Related Posts

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im[...]

Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer

Chandrasekhar A, Yang HC, Demir T, Yeldandi A, Kurihara C, Tomic R, Gao R, Goldman JW, Nadig S, Chae YK, Bharat A. Multiorgan transplant for[...]

MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin

Fu X, Ma J, Ma F, Guo S, Wang X, Li Y, Tang Y, Qi J, Zhang W, Ye L. MISP-mediated enhancement of pancreatic cancer[...]